TransCode Reports Positive Phase 1a Results for TTX-MC138 in Metastatic Cancer
BOSTON, Massachusetts, October 14, 2025 — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) today announced encouraging preliminary data from its completed...
ESMO 2025
Advertisement
AstraZeneca Unveils Landmark Cancer Trial Results at ESMO 2025
Madrid, Spain – October 11, 2025 – AstraZeneca presented groundbreaking clinical trial results from four major Phase III studies...
Novartis to Present Key Prostate and Breast Cancer Data at ESMO
BASEL, Switzerland, Sept. 26, 2025 — Novartis announced it will present 34 abstracts from its oncology pipeline at the...
SystImmune Showcases Pivotal ADC Data at ESMO 2025, Strengthening Next-Generation Cancer Pipeline
REDMOND, Wash., Sept. 24, 2025 – SystImmune, Inc. announced the upcoming presentation of new clinical data on izalontamab brengitecan...
Advertisement
